RecruitingPhase 2NCT07399067

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof-of-Concept Study to Evaluate the Efficacy and Safety of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment

120 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dupilumab, a drug called IBI3002, and others for people with atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIBI3002

IBI3002 will be administered subcutaneously at the assigned dose level and dosing interval.

DRUGPlacebo

Matched placebo will be administered subcutaneously at the same schedule as IBI3002.

DRUGDupilumab

Dupilumab 300mg Q2w, with a loading dose of 600mg, will be administered subcutaneously.

Locations(1)

China-japan Friendship Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07399067

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT068992041 location

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT0723994710 locations

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT065643895 locations

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT0680728137 locations